| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
CareDx Inc (NASDAQ: CDNA)
CDNA Technical Analysis
5
| As on 9th Jun 2023 CDNA STOCK Price closed @ 7.79 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 27.79 & Strong Sell for SHORT-TERM with Stoploss of 40.64 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CDNASTOCK Price
| Open | 8.14 | Change | Price | % |
| High | 8.15 | 1 Day | -0.27 | -3.35 |
| Low | 7.75 | 1 Week | -0.19 | -2.38 |
| Close | 7.79 | 1 Month | 0.01 | 0.13 |
| Volume | 575800 | 1 Year | -37.65 | -82.86 |
| 52 Week High 46.60 | 52 Week Low 7.61 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CDNA Daily Charts |
CDNA Intraday Charts |
Whats New @ Bazaartrend |
CDNA Free Analysis |
|
|
CDNA Important Levels Intraday
| RESISTANCE | 8.56 |
| RESISTANCE | 8.31 |
| RESISTANCE | 8.16 |
| RESISTANCE | 8.01 |
| SUPPORT | 7.57 |
| SUPPORT | 7.42 |
| SUPPORT | 7.27 |
| SUPPORT | 7.02 |
CDNA Forecast April 2024
| 4th UP Forecast | 30.34 |
| 3rd UP Forecast | 23.11 |
| 2nd UP Forecast | 18.64 |
| 1st UP Forecast | 14.17 |
| 1st DOWN Forecast | 1.41 |
| 2nd DOWN Forecast | -3.06 |
| 3rd DOWN Forecast | -7.53 |
| 4th DOWN Forecast | -14.76 |
CDNA Weekly Forecast
| 4th UP Forecast | 17.98 |
| 3rd UP Forecast | 14.71 |
| 2nd UP Forecast | 12.69 |
| 1st UP Forecast | 10.67 |
| 1st DOWN Forecast | 4.91 |
| 2nd DOWN Forecast | 2.89 |
| 3rd DOWN Forecast | 0.87 |
| 4th DOWN Forecast | -2.40 |
CDNA Forecast2024
| 4th UP Forecast | 87.95 |
| 3rd UP Forecast | 62.24 |
| 2nd UP Forecast | 46.35 |
| 1st UP Forecast | 30.46 |
| 1st DOWN Forecast | -14.88 |
| 2nd DOWN Forecast | -30.77 |
| 3rd DOWN Forecast | -46.66 |
| 4th DOWN Forecast | -72.37 |
CareDx Inc ( NASDAQ USA Symbol : CDNA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CDNA Business Profile
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. It also has a collaborative research agreement with Eledon Pharmaceuticals, Inc. to use AlloSure for assessing the efficacy of Eledon's investigational AT-1501 in the prevention of rejection in upcoming renal transplantation trials. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California. Address: 1 Tower Place, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service